Market closed
Biogen/$BIIB
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Biogen
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
Ticker
$BIIB
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
7,605
Website
Biogen Metrics
BasicAdvanced
$17B
10.63
$11.18
0.01
-
Price and volume
Market cap
$17B
Beta
0.01
52-week high
$238.00
52-week low
$110.04
Average daily volume
1.8M
Financial strength
Current ratio
1.349
Quick ratio
0.768
Long term debt to equity
29.204
Total debt to equity
39.664
Interest coverage (TTM)
9.28%
Management effectiveness
Return on assets (TTM)
5.29%
Return on equity (TTM)
10.36%
Valuation
Price to earnings (TTM)
10.63
Price to revenue (TTM)
1.788
Price to book
1.04
Price to tangible book (TTM)
31.74
Price to free cash flow (TTM)
6.017
Growth
Revenue change (TTM)
-1.62%
Earnings per share change (TTM)
40.28%
3-year revenue growth (CAGR)
-4.13%
3-year earnings per share growth (CAGR)
2.44%
What the Analysts think about Biogen
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Biogen stock.
Biogen Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Biogen Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Biogen News
AllArticlesVideos
Biogen: Is This A Value Trap, Or Is The Great Turnaround Imminent?
Seeking Alpha·3 days ago
Leqembi®∇ (lecanemab) is the First Medicine that Slows Progression of Early Alzheimer's Disease to be Authorized in the European Union
GlobeNewsWire·2 weeks ago
EU authorizes Eisai-Biogen's drug for treatment of early Alzheimer's disease
Reuters·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Biogen stock?
Biogen (BIIB) has a market cap of $17B as of April 28, 2025.
What is the P/E ratio for Biogen stock?
The price to earnings (P/E) ratio for Biogen (BIIB) stock is 10.63 as of April 28, 2025.
Does Biogen stock pay dividends?
No, Biogen (BIIB) stock does not pay dividends to its shareholders as of April 28, 2025.
When is the next Biogen dividend payment date?
Biogen (BIIB) stock does not pay dividends to its shareholders.
What is the beta indicator for Biogen?
Biogen (BIIB) has a beta rating of 0.01. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.